Completed OBSERVATIONAL NCT01060059

Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes

EBIRIOS - Exenatide and Basal Insulins Use in the Real Setting: an Italian Observational Study in Patients With Type 2 Diabetes and Secondary Failure of Oral Antihyperglycemic Treatment

Sponsor: AstraZeneca

Conditions Type 2 Diabetes Mellitus

Interventions basal insulin exenatide

Updated 8 times since 2017 Last updated: Mar 20, 2015 Started: Apr 30, 2010 Primary completion: May 31, 2012 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Type 2 Diabetes Mellitus and is currently completed. AstraZeneca leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Eli Lilly and Company

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Acquaviva delle Fonti, Italy , Anzio, Italy , Bassano del Grappa, Italy , Bologna, Italy , Brindisi, Italy , Cagliari, Italy , Campi Salentina, Italy , Casarano, Italy , Caserta, Italy , Cesena, Italy and 40 more locations